We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Byondis Reports Positive Late-Stage Trial Findings for Antibody Drug Conjugate in HER2-Positive Breast Cancer
Byondis Reports Positive Late-Stage Trial Findings for Antibody Drug Conjugate in HER2-Positive Breast Cancer
Byondis, a Dutch biopharma company focused on oncology drugs, reported that its late-stage trial evaluating its antibody-drug conjugate candidate in HER2-positive breast cancer met its primary endpoint, a development that’s given it confidence to file for FDA approval by the end of the year.